Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder

BackgroundDesvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, has demonstrated efficacy in improving affective symptoms of Major Depressive Disorder (MDD); however, its effects on associated cognitive and functional difficulties remain underexplored. This study seeks to assess the antidep...

Descripción completa

Detalles Bibliográficos
Autores: Vicent Gil, Muriel, Trujols i Albet, Joan, Sagues, Teresa, Serra Blasco, María, Navarra Ventura, Guillem, Mantellini, Cecilia L., Crivilles, Sara, Portella, Maria J., Cardoner, N. (Narcís)
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/221542
Acceso en línea:https://hdl.handle.net/2445/221542
Access Level:acceso abierto
Palabra clave:Depressió psíquica
Terapèutica
Mental depression
Therapeutics
id ES_3c2127f5fd2a710d81c8a64f14dab64d
oai_identifier_str oai:diposit.ub.edu:2445/221542
network_acronym_str ES
network_name_str España
repository_id_str
spelling Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorderVicent Gil, MurielTrujols i Albet, JoanSagues, TeresaSerra Blasco, MaríaNavarra Ventura, GuillemMantellini, Cecilia L.Crivilles, SaraPortella, Maria J.Cardoner, N. (Narcís)Depressió psíquicaTerapèuticaMental depressionTherapeuticsBackgroundDesvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, has demonstrated efficacy in improving affective symptoms of Major Depressive Disorder (MDD); however, its effects on associated cognitive and functional difficulties remain underexplored. This study seeks to assess the antidepressant effects of desvenlafaxine in patients with SSRI-resistant MDD, its impact on both objective and subjective cognitive performance, where cognitive improvements occur independently of clinical recovery or not, and its influence on psychosocial functioning.MethodsAn observational case-control prospective study with 66 participants was conducted, including 26 patients with a current MDD episode, with an inadequate SSRI response, and with the prescription of desvenlafaxine as the next antidepressant therapeutic option, and 40 healthy controls. Sociodemographic, clinical, cognitive, and functional assessments were conducted both before and after a 12-week treatment period. Changes were analyzed using two tailed paired-samples t-tests, with Cohen's d for effect sizes. Cognitive improvements were compared between the patients who achieved remission and those who did not.ResultsPatients showed significant improvements in depressive and anxiety symptoms, attention/working memory and processing speed, self-perceived cognitive difficulties and psychosocial functioning. Highlighting the fact these cognitive enhancements occurred independently of patients' clinical improvement.ConclusionsThe findings of this study focus on the therapeutic potential of desvenlafaxine, demonstrating its efficacy not only in ameliorating clinical and functional symptoms but also in addressing specific cognitive impairments in patients with depression. Further research is needed to elucidate the mechanisms underlying desvenlafaxine's effects and optimize treatment strategies for individuals with MDD.Trial registration numberNCT03432221 (clinical.trials.gov). Registration date: 08-01-2018.Springer Science and Business Media LLC2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/221542Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1186/s12991-025-00552-2Annals of General Psychiatry, 2025, vol. 24https://doi.org/10.1186/s12991-025-00552-2cc-by-nc-nd (c) Vicent Gil et al., 2025http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2215422026-05-27T06:46:51Z
dc.title.none.fl_str_mv Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
title Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
spellingShingle Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
Vicent Gil, Muriel
Depressió psíquica
Terapèutica
Mental depression
Therapeutics
title_short Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
title_full Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
title_fullStr Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
title_full_unstemmed Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
title_sort Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
dc.creator.none.fl_str_mv Vicent Gil, Muriel
Trujols i Albet, Joan
Sagues, Teresa
Serra Blasco, María
Navarra Ventura, Guillem
Mantellini, Cecilia L.
Crivilles, Sara
Portella, Maria J.
Cardoner, N. (Narcís)
author Vicent Gil, Muriel
author_facet Vicent Gil, Muriel
Trujols i Albet, Joan
Sagues, Teresa
Serra Blasco, María
Navarra Ventura, Guillem
Mantellini, Cecilia L.
Crivilles, Sara
Portella, Maria J.
Cardoner, N. (Narcís)
author_role author
author2 Trujols i Albet, Joan
Sagues, Teresa
Serra Blasco, María
Navarra Ventura, Guillem
Mantellini, Cecilia L.
Crivilles, Sara
Portella, Maria J.
Cardoner, N. (Narcís)
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Depressió psíquica
Terapèutica
Mental depression
Therapeutics
topic Depressió psíquica
Terapèutica
Mental depression
Therapeutics
description BackgroundDesvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, has demonstrated efficacy in improving affective symptoms of Major Depressive Disorder (MDD); however, its effects on associated cognitive and functional difficulties remain underexplored. This study seeks to assess the antidepressant effects of desvenlafaxine in patients with SSRI-resistant MDD, its impact on both objective and subjective cognitive performance, where cognitive improvements occur independently of clinical recovery or not, and its influence on psychosocial functioning.MethodsAn observational case-control prospective study with 66 participants was conducted, including 26 patients with a current MDD episode, with an inadequate SSRI response, and with the prescription of desvenlafaxine as the next antidepressant therapeutic option, and 40 healthy controls. Sociodemographic, clinical, cognitive, and functional assessments were conducted both before and after a 12-week treatment period. Changes were analyzed using two tailed paired-samples t-tests, with Cohen's d for effect sizes. Cognitive improvements were compared between the patients who achieved remission and those who did not.ResultsPatients showed significant improvements in depressive and anxiety symptoms, attention/working memory and processing speed, self-perceived cognitive difficulties and psychosocial functioning. Highlighting the fact these cognitive enhancements occurred independently of patients' clinical improvement.ConclusionsThe findings of this study focus on the therapeutic potential of desvenlafaxine, demonstrating its efficacy not only in ameliorating clinical and functional symptoms but also in addressing specific cognitive impairments in patients with depression. Further research is needed to elucidate the mechanisms underlying desvenlafaxine's effects and optimize treatment strategies for individuals with MDD.Trial registration numberNCT03432221 (clinical.trials.gov). Registration date: 08-01-2018.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/221542
url https://hdl.handle.net/2445/221542
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1186/s12991-025-00552-2
Annals of General Psychiatry, 2025, vol. 24
https://doi.org/10.1186/s12991-025-00552-2
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Vicent Gil et al., 2025
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Vicent Gil et al., 2025
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Science and Business Media LLC
publisher.none.fl_str_mv Springer Science and Business Media LLC
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406349770620928
score 15,812429

Similares en LA Referencia